Advantage Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Advantage Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25	Closed	-$18K	–	1054
2018 Q2	$18K	Sell	25 -337	-93%	-$389K	0.01%	561
2018 Q1	$578K	Sell	362 -225	-38%	-$290K	0.22%	96
2017 Q4	$526K	Sell	587 -335	-36%	-$198K	0.16%	110
2017 Q3	$332K	Buy	922 +37	+4%	+$11.6K	0.11%	130
2017 Q2	$260K	Buy	885 +855	+2,850%	+$247K	0.09%	144
2017 Q1	$10K	Buy	+30	New	+$6.74K	﹤0.01%	686

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Advantage Investment Management's NKTR Position: Q3 2018 in Review

Advantage Investment Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 25 shares — an estimated $18K sold.

Advantage Investment Management first reported a position in NKTR in Q1 2017 and held it in 6 quarters. The position peaked at $578K in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

Advantage Investment Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
Advantage Investment Management sold 25 Nektar Therapeutics shares in Q3 2018, an estimated $18K.
Advantage Investment Management first reported a position in Nektar Therapeutics in Q1 2017 and held it in 6 quarters.
Advantage Investment Management's Nektar Therapeutics position peaked at $578K in Q1 2018.
389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Advantage Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.